Cargando…
HER3 in cancer: from the bench to the bedside
The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is expressed in several types of tumors. That fact, together with the role of HER3 in promoting cell proliferation, implicate that targeting HER3 may have therapeutic relevance. Furthermore, expression and activati...
Autores principales: | Gandullo-Sánchez, Lucía, Ocaña, Alberto, Pandiella, Atanasio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585794/ https://www.ncbi.nlm.nih.gov/pubmed/36271429 http://dx.doi.org/10.1186/s13046-022-02515-x |
Ejemplares similares
-
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021) -
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020) -
Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021) -
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020) -
Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)